免疫治疗联合化疗治疗晚期非小细胞肺癌患者的成本效用分析的系统评价

Systematic Evaluation of Cost-Utility Analysis of Immunotherapy Combined with Chemotherapy for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

摘要: 目的：本研究旨在对我国晚期非小细胞肺癌的一线治疗方案相关药物的药物经济学评价进行分析，为我国的晚期非小细胞肺癌的一线治疗方案的药物经济学提供循证参考。方法：检索中华医学网、万方、Pubmed、Embase、Web of Science等数据库，分析纳入模型、成本产出指标等相关要素。结果：共纳入9篇文献，均为英文文献，纳入的文献主要为免疫治疗联合化疗与化疗药物之间经济学对比，也有部分免疫治疗联合化疗方案之间对比，所有的疗效数据均来源于临床实验，在晚期非小细胞肺癌患者使用免疫治疗联合化疗方案与单纯化疗方案的经济学对比之间，免疫治疗联合化疗较单纯化疗更具有经济学效益，但免疫治疗联合化疗之间，可参考本研究纳入相关文献，为大家提供相关参考依据。结论：结合现有的研究结果可表明在晚期非小细胞肺癌患者中使用免疫治疗联合化疗更具有经济学效益，在所纳入的免疫治疗联合化疗治疗晚期非小细胞肺癌患者中，信迪利单抗联合化疗方案虽更具有成本效益，但目前纳入文献较少，缺乏相关实验比对，且大多数纳入均为直接医疗成本，局限性较大。因此，本研究系探讨我国对于治疗晚期非小细胞肺癌一线免疫治疗药物的成本效益以及为我国医疗保健系统提供循证参考依据。

Abstract: Objective: The aim of this study was to analyze the pharmacoeconomic evaluation of drugs related to the first-line treatment regimen for advanced non-small cell lung cancer in China, and to provide evidence-based reference for the pharmacoeconomics of the first-line treatment regimen for ad-vanced non-small cell lung cancer in China. Methods: We searched the databases of China Medical Network, Wanfang, Pubmed, Embase, Web of Science, and analyzed the inclusion model, cost and output indicators and other related elements. Results: A total of nine papers were included, all of which were in English, and the included papers were mainly economic comparisons between im-munotherapy-combination chemotherapy and chemotherapeutic agents, and some comparisons between immunotherapy-combination chemotherapy regimens, and all of the efficacy data came from clinical trials, and among the economic comparisons between the use of immunothera-py-combination chemotherapy regimen and the chemotherapy alone regimen in patients with ad-vanced non-small-cell lung cancer, the immunotherapy-combination chemotherapy had more eco-nomic benefits than chemotherapy alone is more economically effective, but between immuno-therapy combination chemotherapy, this study can be referred to the inclusion of relevant litera-ture to provide a relevant reference point. Conclusion: The combination of existing research results can show that the use of immunotherapy combination chemotherapy is more economically benefi-cial in patients with advanced non-small cell lung cancer, in the included immunotherapy combina-tion chemotherapy treatment of patients with advanced non-small cell lung cancer, sindilizumab combination chemotherapy regimen is more cost-effective, but the current inclusion of the litera-ture is relatively small, lack of relevant experimental comparisons, and most of the inclusion is in direct medical costs, which is a limitation. Therefore, the present study was designed to explore the cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer in China and to provide an evidence-based reference for the healthcare system in China.